Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$23.44
1.185.30%
At close: -
$23.44
0.000.00%
After Hours: 4:34 PM EDT
Comments
Loading...
Edgewise Therapeutics Analyst Ratings and Price Targets | NASDAQ:EWTX | Benzinga
Edgewise Therapeutics Inc has a consensus price target of $39.8 based on the ratings of 10 analysts. The high is $56 issued by RBC Capital on March 4, 2025. The low is $5 issued by Goldman Sachs on August 25, 2022. The 3 most-recent analyst ratings were released by Scotiabank, RBC Capital, and Stifel on March 7, 2025, March 4, 2025, and January 22, 2025, respectively. With an average price target of $45.33 between Scotiabank, RBC Capital, and Stifel, there's an implied 93.40% upside for Edgewise Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Scotiabank
RBC Capital
Stifel
Evercore ISI Group
Truist Securities
1calculated from analyst ratings
Analyst Ratings for Edgewise Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/07/2025 | Buy Now | 113.31% | Scotiabank | Louise Chen58% | → $50 | Initiates | → Sector Outperform | Get Alert |
| 03/04/2025 | Buy Now | 138.91% | RBC Capital | Leonid Timashev45% | $56 → $56 | Reiterates | Outperform → Outperform | Get Alert |
| 01/22/2025 | Buy Now | 27.99% | Stifel | James Condulis39% | → $30 | Initiates | → Hold | Get Alert |
| 12/17/2024 | Buy Now | 113.31% | Evercore ISI Group | Cory Kasimov70% | $45 → $50 | Maintains | Outperform | Get Alert |
| 11/27/2024 | Buy Now | 113.31% | Truist Securities | Srikripa Devarakonda48% | $33 → $50 | Maintains | Buy | Get Alert |
| 11/22/2024 | Buy Now | 91.98% | Evercore ISI Group | Cory Kasimov70% | → $45 | Initiates | → Outperform | Get Alert |
| 11/08/2024 | Buy Now | 91.98% | Wedbush | Laura Chico47% | $44 → $45 | Maintains | Outperform | Get Alert |
| 10/11/2024 | Buy Now | 117.58% | Piper Sandler | Yasmeen Rahimi60% | $48 → $51 | Maintains | Overweight | Get Alert |
| 09/20/2024 | Buy Now | 79.18% | RBC Capital | Leonid Timashev45% | $32 → $42 | Maintains | Outperform | Get Alert |
| 09/19/2024 | Buy Now | 40.78% | Truist Securities | Srikripa Devarakonda48% | $25 → $33 | Maintains | Buy | Get Alert |
| 09/17/2024 | Buy Now | 36.52% | RBC Capital | Leonid Timashev45% | $32 → $32 | Maintains | Outperform | Get Alert |
| 08/16/2024 | Buy Now | 32.25% | Wedbush | Laura Chico47% | $31 → $31 | Reiterates | Outperform → Outperform | Get Alert |
| 08/12/2024 | Buy Now | 32.25% | JP Morgan | Tessa Romero62% | $30 → $31 | Maintains | Overweight | Get Alert |
| 07/25/2024 | Buy Now | 36.52% | RBC Capital | Leonid Timashev45% | $32 → $32 | Reiterates | Outperform → Outperform | Get Alert |
| 07/10/2024 | Buy Now | 36.52% | RBC Capital | Leonid Timashev45% | $32 → $32 | Reiterates | Outperform → Outperform | Get Alert |
| 07/09/2024 | Buy Now | 27.99% | JP Morgan | Tessa Romero62% | $27 → $30 | Maintains | Overweight | Get Alert |
| 07/01/2024 | Buy Now | 104.78% | Piper Sandler | Yasmeen Rahimi60% | $48 → $48 | Maintains | Overweight | Get Alert |
| 06/26/2024 | Buy Now | 32.25% | Wedbush | Laura Chico47% | $31 → $31 | Reiterates | Outperform → Outperform | Get Alert |
| 04/22/2024 | Buy Now | 36.52% | RBC Capital | Leonid Timashev45% | $28 → $32 | Maintains | Outperform | Get Alert |
| 04/17/2024 | Buy Now | 6.66% | Truist Securities | Srikripa Devarakonda48% | $25 → $25 | Maintains | Buy | Get Alert |
| 04/16/2024 | Buy Now | 10.92% | Wedbush | Laura Chico47% | $26 → $26 | Reiterates | Outperform → Outperform | Get Alert |
| 03/12/2024 | Buy Now | 19.45% | RBC Capital | Leonid Timashev45% | $28 → $28 | Reiterates | Outperform → Outperform | Get Alert |
| 03/07/2024 | Buy Now | 104.78% | Piper Sandler | Yasmeen Rahimi60% | → $48 | Initiates | → Overweight | Get Alert |
| 11/10/2023 | Buy Now | -1.88% | Wedbush | Laura Chico47% | $27 → $23 | Maintains | Outperform | Get Alert |
| 08/16/2023 | Buy Now | 15.19% | Wedbush | Laura Chico47% | → $27 | Reiterates | Outperform → Outperform | Get Alert |
| 08/11/2023 | Buy Now | 15.19% | Wedbush | Laura Chico47% | → $27 | Reiterates | Outperform → Outperform | Get Alert |
| 06/30/2023 | Buy Now | 6.66% | JP Morgan | Tessa Romero62% | $24 → $25 | Maintains | Overweight | Get Alert |
| 06/28/2023 | Buy Now | 6.66% | Truist Securities | Srikripa Devarakonda48% | → $25 | Reiterates | Buy → Buy | Get Alert |
| 06/28/2023 | Buy Now | 19.45% | RBC Capital | Leonid Timashev45% | → $28 | Reiterates | Outperform → Outperform | Get Alert |
| 06/27/2023 | Buy Now | 6.66% | Truist Securities | Srikripa Devarakonda48% | → $25 | Reiterates | Buy → Buy | Get Alert |
| 05/16/2023 | Buy Now | 2.39% | JP Morgan | Tessa Romero62% | $25 → $24 | Maintains | Overweight | Get Alert |
| 05/12/2023 | Buy Now | 15.19% | Wedbush | Laura Chico47% | → $27 | Reiterates | Outperform → Outperform | Get Alert |
| 05/01/2023 | Buy Now | 6.66% | Truist Securities | Srikripa Devarakonda48% | → $25 | Initiates | → Buy | Get Alert |
| 02/28/2023 | Buy Now | 6.66% | JP Morgan | Tessa Romero62% | $27 → $25 | Maintains | Overweight | Get Alert |
| 11/04/2022 | Buy Now | 23.72% | RBC Capital | Leonid Timashev45% | $31 → $29 | Maintains | Outperform | Get Alert |
| 08/25/2022 | Buy Now | -78.67% | Goldman Sachs | Madhu Kumar72% | → $5 | Downgrade | Neutral → Sell | Get Alert |
| 05/24/2022 | Buy Now | -78.67% | Goldman Sachs | Madhu Kumar72% | $8 → $5 | Maintains | Neutral | Get Alert |
| 05/12/2022 | Buy Now | -65.87% | Goldman Sachs | Madhu Kumar72% | $11 → $8 | Maintains | Neutral | Get Alert |
| 05/12/2022 | Buy Now | 27.99% | SVB Leerink | Joseph Schwartz50% | $34 → $30 | Maintains | Outperform | Get Alert |
| 04/13/2022 | Buy Now | 32.25% | RBC Capital | Leonid Timashev45% | → $31 | Initiates | → Outperform | Get Alert |
FAQ
What is the target price for Edgewise Therapeutics (EWTX) stock?
The latest price target for Edgewise Therapeutics (NASDAQ:EWTX) was reported by Scotiabank on March 7, 2025. The analyst firm set a price target for $50.00 expecting EWTX to rise to within 12 months (a possible 113.31% upside). 21 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Edgewise Therapeutics (EWTX)?
The latest analyst rating for Edgewise Therapeutics (NASDAQ:EWTX) was provided by Scotiabank, and Edgewise Therapeutics initiated their sector outperform rating.
When was the last upgrade for Edgewise Therapeutics (EWTX)?
There is no last upgrade for Edgewise Therapeutics
When was the last downgrade for Edgewise Therapeutics (EWTX)?
The last downgrade for Edgewise Therapeutics Inc happened on August 25, 2022 when Goldman Sachs changed their price target from N/A to $5 for Edgewise Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Edgewise Therapeutics (EWTX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Edgewise Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Edgewise Therapeutics was filed on March 7, 2025 so you should expect the next rating to be made available sometime around March 7, 2026.
Is the Analyst Rating Edgewise Therapeutics (EWTX) correct?
While ratings are subjective and will change, the latest Edgewise Therapeutics (EWTX) rating was a initiated with a price target of $0.00 to $50.00. The current price Edgewise Therapeutics (EWTX) is trading at is $23.44, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.